UK's Syncona writes off 54.5 mln stg after Novartis ends Gyroscope's therapy
11/09/2023 07:32
Sept 11 (Reuters) - British healthcare investment firm
Syncona SYNCS.L said on Monday Novartis NOVN.S has stopped
the development of experimental eye treatment, GT005, which
would result in payments write-off of 54.5 million pounds
($68.23 million) for Gyroscope Holdings Limited.
($1 = 0.7987 pounds)
(Reporting by Radhika Anilkumar in Bengaluru;Editing by Dhanya
Ann Thoppil)
((Radhika.Anilkumar@thomsonreuters.com;))
Recent news on Syncona
See all newsBrief: Syncona Reports Net Assets Of £1.07 Billion, Nav Per Share Of 175.7p, 3.0% Return For Six Months Ended Sept 30, 2026
Syncona Limited - Half-year Report
Syncona Limited - Holding(s) in Company
Brief: Syncona Commits $10.10 Million To OMass $310 Million Series C Financing
Syncona Limited - OMass raises $310 million in Series C financing